Abstract
AbstractABO blood group compatibility restrictions present the first barrier to donor-recipient matching in kidney transplantation. Here, we present the use of two enzymes, FpGalNAc deacetylase and FpGalactosaminidase, from the bacterium Flavonifractor plautii to enzymatically convert blood group A antigens from the renal vasculature of human kidneys to ‘universal’ O-type. Using normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP) strategies, we demonstrate blood group A antigen loss of approximately 80% in as little as 2 h NMP and HMP. Furthermore, we show that treated kidneys do not bind circulating anti-A antibodies in an ex vivo model of ABO-incompatible transplantation and do not activate the classical complement pathway. This strategy presents a solution to the donor organ shortage crisis with the potential for direct clinical translation to reduce waiting times for patients with end stage renal disease.
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Annual Activity Report. ODT Clinical - NHS Blood and Transplant https://www.odt.nhs.uk/statistics-and-reports/annual-activity-report/.
2. Böhmig, G. A., Farkas, A. M., Eskandary, F. & Wekerle, T. Strategies to overcome the ABO barrier in kidney transplantation. Nat. Rev. Nephrol. 11, 732–747 (2015).
3. MacMillan, S., Hosgood, S. A. & Nicholson, M. L. Enzymatic blood group conversion of human kidneys during ex vivo normothermic machine perfusion. Br. J. Surg. 110, 133–137 (2022).
4. Wang, A. et al. Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs. Sci. Transl. Med. 14, eabm7190 (2022).
5. Gilmour, J., Griffiths, C., Pither, T., Scott, W. E. I. & Fisher, A. J. Normothermic machine perfusion of donor-lungs ex-vivo: promoting clinical adoption. Curr. Opin. Organ Transplant. 25, 285 (2020).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献